VistaGen completes PALISADE-4 phase 3 study of fasedienol for social anxiety
Tweet Send to a Friend
VistaGen (NASDAQ: VTGN) announced the completion of the last patient visit in the randomized portion of its PALISADE-4 Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
